Comprehensive Skyrizi Market Insights: Forecasting Size, Growth, and Competitive Trends from 2025 to 2034

What Is the Future Outlook for the Skyrizi Market's Size and Growth Rate?_x000D_
In recent times, the market size for Skyrizi has experienced $XX (CAGR). With projections estimating a surge from $XX million in 2024 to $XX million in 2025, representing a compound annual growth rate (CAGR) of $XX%. The noticeable growth during the past years is due to factors like increasing recognition of chronic inflammatory diseases, the prevalence of biosimilars, greater access to global healthcare, expansion of clinical indications, and the availability of extensive long-term safety data._x000D_
_x000D_
Anticipations for the Skyrizi market size reveal a Compound Annual Growth Rate (CAGR) of $XX% within the following years, putting the market value at $XX million by 2029. The predicted expansion during the forecast period is driven by its increasing use in psoriasis treatment, surging patient numbers, a growing elderly population, better awareness and diagnosis, and a rise in processed foods consumption. Foreseen market trends for the period include technological advancements in biologics, a leaning towards combination therapies, progress in diagnostic technologies, a transition from oral to injection-based treatments, and the utilization of artificial intelligence in drug development._x000D_
_x000D_
What Is Stimulating Growth in the Skyrizi Market?_x000D_
The increasing incidence of psoriasis is anticipated to accelerate the expansion of the Skyrizi market. Psoriasis, a chronic autoimmune disease that results in a swift accumulation of skin cells, causing skin scaling, is becoming more common. This increasing incidence can be ascribed to factors such as genetic susceptibility, environmental stimuli, greater awareness and diagnosis rates, lifestyle modifications, and the intensifying influence of stress and immune-related ailments on overall health. Skyrizi, an interleukin-23 (IL-23) targeting biologic therapy, is beneficial in psoriasis treatment by specifically inhibiting this cytokine, instrumental in inflammation, thereby decreasing skin inflammation. It eases symptoms such as redness and scaling, enhancing skin clearance in patients suffering from moderate to severe plaque psoriasis. For instance, in December 2022, the National Psoriasis Foundation (NPF), a nonprofit organization based in the U.S., estimated that 8 million Americans and 125 million people around the world (2-3% of the global population) have psoriasis. Furthermore, about 30% of psoriasis patients also develop psoriatic arthritis. Hence, the growing incidence of psoriasis propels the development of the Skyrizi market._x000D_
_x000D_
Get Your Free Sample Now - Explore Exclusive Market Insights:_x000D_
https://www.thebusinessresearchcompany.com/sample.aspx?id=20266&type=smp_x000D_
_x000D_
Which Key Market Leaders Are Driving Skyrizi Industry Growth?_x000D_
Major companies operating in the skyrizi market are AbbVie Inc. _x000D_
_x000D_
What Are the Emerging Trends in the Skyrizi Industry?_x000D_
The skyrizi market is on trend toward emphasizing the expansion of treatment indications such as ulcerative colitis in a bid to improve therapeutic outcomes for autoimmune conditions. The approval of Skyrizi for the treatment of moderate-to-severe ulcerative colitis (UC), which has resulted in significant clinical improvements in patients who have exhibited resistance to other forms of treatment, exhibits this trend. AbbVie Inc., an American biopharmaceutical firm, for instance, secured the approval of the European Commission in July 2024 to use Skyrizi (risankizumab) in treating adult patients with moderately to severely active UC who failed to respond to, or are intolerant to, conventional or biologic therapies. Such approval has hinged on the favorable results gleaned from the Phase 3 INSPIRE and COMMAND trials, which distinctly highlighted mucosal healing in patients without any history of biologic or JAK inhibitor use. The dosing regimen of Skyrizi includes an initial 1,200 mg dose, followed by 180 mg or 360 mg maintenance doses every 8 weeks._x000D_
_x000D_
What Are the Main Segments in the Skyrizi Market?_x000D_
The skyrizi market covered in this report is segmented - _x000D_
_x000D_
1) By Indication: Plaque Psoriasis; Crohn's Disease; Ulcerative Colitis_x000D_
2) By Formulation: Pre-Filled Syringes; Vials_x000D_
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies_x000D_
_x000D_
Pre-Book Your Report Now For A Swift Delivery:_x000D_
https://www.thebusinessresearchcompany.com/report/skyrizi-global-market-report_x000D_
_x000D_
Which Geographic Area Leads the Skyrizi Market?_x000D_
North America was the largest region in the skyrizi market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the skyrizi market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_
_x000D_
What Is Covered In The Skyrizi Global Market Report?_x000D_
_x000D_
- Market Size Analysis: Analyze the skyrizi Market size by key regions, countries, product types, and applications._x000D_
- Market Segmentation Analysis: Identify various subsegments within the skyrizi Market for effective categorization._x000D_
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape._x000D_
- Growth Trends Analysis: Examine individual growth trends and prospects in the market._x000D_
- Market Contribution: Evaluate contributions of different segments to the overall skyrizi market growth._x000D_
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers._x000D_
- Industry Challenges: Analyze challenges and risks affecting the skyrizi market._x000D_
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market._x000D_
_x000D_
Unlock Exclusive Market Insights - Purchase Your Research Report Now!_x000D_
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20266_x000D_
_x000D_

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.